# Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

> **NCT01891981** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Moxetumomab Pasudotox

## Key facts

- **NCT ID:** NCT01891981
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12-17
- **Primary completion:** 2017-04-12
- **Final completion:** 2017-04-12
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter
- **Last updated:** 2023-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01891981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01891981, "Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01891981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*